Plague

Vaccine

Volumn 27, Issue SUPPL. 4, 2009, Pages

  Williamson, E D ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Clinical studies; Mechanisms of protection; Non clinical; Pneumonic plague

Indexed keywords

IMMUNOGLOBULIN G; RECOMBINANT VACCINE; VACCINE;

ARTICLE; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MANUFACTURE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPROPHYLAXIS; LICENCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLAGUE; PRIORITY JOURNAL; PROPHYLAXIS; TECHNOLOGY; VACCINATION;

EID: 77957748020     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.068     Document Type: Article

References (51)

1. Achtman M, Zurth K, Moerlli G, Torrea G, Guiyoule A, Carniel E. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis, vol. 96. USA: PNAS; 1999. p. 14043-14048.
2. Doll JM, Zeitz PS, Ettestad P, Bucholtz AL, Davis T, Gage K. Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. Am J Trop Med Hyg 1994;51:109-14.
3. Perry RD, Fetherston JD. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 1997;10:35-66.
4. Guiyoule A, Rasaomanana B, Buchrieser C, Michel P, Chanteau S, Carniel E. Recent emergence of newvariants of Yersinia pestis in Madagascar. J Clin Microbiol 1997;35:2826-33.
5. Dennis DT, Gage KL, Grantz N, Poland JD, Tikhomirov E. Plague manual: epidemiology, distribution surveillance and control. Geneva: WHO; 1999.
6. Anonymous. Humanplague in 1998 and 1999.World Health Organisation. Wkly Epidemiol Rec 2000;75:337-44.
7. Guiyoule A, Gerbaud G, Buchrieser C, Galimand M, Rahalison L, Chanteau S, et al. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg Infect Dis 2001;7:43-8.
8. Cavanaugh DC, Elisberg BL, Llewellyn CH, Marshall JD, Rust JH, Williams JE, et al. Plague immunization. V. Indirect evidence for the efficacy of plague vaccine. J Infect Dis 1974;129:S37-40.
9. Anderson GW, Leary SEC, Williamson ED, Titball RW, Welkos SL, Worsham PL, et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and negative strains of Y. pestis. Infect Immun 1996;64:4580-5.
10. Williamson ED, Eley SM, Griffin KF, Green M, Russell P, Leary SEC, et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 1995;12:223-30.
11. Andrews GP, Strachan ST, Benner GE, Sample AK, Anderson GW, Adamovicz JJ, et al. Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis. Infect Immun 1999;67:1533-7.
12. Quenee LE, Cornelius CA, Ciletti NA, Elli D, Schneewind O. Yersinia pestis caf1 variants and the limits of plague vaccine protection. Infect Immun 2008;76:2025-36.
13. Heath DG, Anderson GWJ, Mauro JM, Welkos SL, Andrews GP, Adamovicz J, et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V fusion protein vaccine. Vaccine 1998;16:1131-7.
14. Williamson ED, Flick-smith HC, Lebutt CS, Rowland CA, Jones SM, Waters EL, et al. Human immune response to a plague vaccine comprising recombinant F1 and rV antigens. Infect Immun 2005;73:3598-608.
15. Williamson ED, Stagg AJ, Eley SM, Titball RW. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunised animals against pneumonic plague. Vaccine 1997;15:1079-84.
16. Jones SM, Griffin KF, Hodgson I, Williamson ED. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine 2003;21:3912-8.
17. Prior JL, Hitchen PG, Williamson ED, Reason AJ, Morris HR, Dell A, et al. Characterisation of the LPS of Y. pestis. Microb Pathogen 2001;30:49-57.
18. Prior JL, Parkhill J, Hitchen PG, Mungall KL, Stevens K, Morris HR, et al. The failure of different strains of Yersinia pestis to produce lipopolysaccharide Oantigen under different growth conditions is due to mutations in the O-antigen gene cluster. FEMS Microbiol Lett 2001;197:229-33.
19. Lahteenmaki K, Kukkonen M, Korhonen TK. The Pla surface protease/adhesin of Yersinia pestis mediates bacterial invasion into human endothelial cells. FEBS Lett 2001;504:69-72.
20. Leary SEC, Griffin KF, Galyov EE, Hewer J, Williamson ED, Holmstrom A, et al. Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague. Microb Pathogen 1999;26:159-69.
21. Benner GE, Andrews GP, Byrne WR, Strachan SD, Sample AK, Heath DG, et al. Immune response to Yersinia outer proteins and other Y. pestis antigens after experimental plague infection in mice. Infect Immun 1999;67:1922-8.
22. Ivanov MI, Noel BL, Rampersaud R, Mena P, Benach JL, Bliska JB. Vaccination of mice with a yop translocon complex elicits antibodies that are protective against infection with F1-Yersinia pestis. Infect Immun 2008;76:5181-90.
23. Davis AJ, Mecsas J. Mutations in the Yersinia pseudotuberculosis type III secretion system needle protein, YscF, that specifically abrogate effector translocation into host cells. J Bacteriol 2007;189:83-97.
24. Matson JS, Durick KA, Bradley DS, Nilles ML. Immunization of mice with YscF provides protection from Yersinia pestis infections. BioMed Central Microbiol 2005;5:38-55.
25. SodeindeOA, SubrahmanyamYVBK, Stark K, Quan T, Bao Y, Goguen JD. A surface protease and the invasive character of plague. Science 1992;258:1004-7.
26. Lathem WW, Price PA, Miller VL, Goldman WE. A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 2007;315:50-13.
27. Cornelis GR. The yersinia YSC-YOP 'type III' weaponery. Nat Rev Mol Cell Biol 2002;3:742-52.
28. Mueller CA, Broz P, Müller SA, Ringler P, Erne-Brand F, Sorg I, et al. The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 2005;310:674-6.
29. Broz P, Mueller CA, Muller SA, Philippsen IS, Engel A, Cornelis GR. Function and molecular architecture of the Yersinia injectisome tip complex. Mol Microbiol 2007;65:1311-20.
30. Burrows TW. Virulence of Pasteurella pestis and immunity to plague. In: Henle W, Kikuth W, Meyer KF, Nauck EG, Tomcsik J, editors. Ergebnisse der mikrobiologi immunitatsforshing und experimentellen therapie. Band 37. Berlin: Springer-Verlag; 1963. p. 59-113.
31. Lawton WD, Erdman RL, Surgalla MJ. Biosynthesis and purification of V andW antigen in Pasteurella pestis. J Immunol 1963;91:179-84.
32. Williamson ED. Plague vaccine research and development. J Appl Microbiol 2001;91:606-8.
33. Williamson ED, Flick Smith HC, Waters EL, Miller J, Hodgson I, Smith S, et al. Immunogenicity of the rF1 + rV vaccine with the identification of potential immune correlates of protection. Microb Pathogen 2007;42:12-22.
34. Cornelius CA, Quenee LE, Overheim KA, Frederick Koster, Brasel TL, Derek Elli, et al. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun 2008;76:5588-97.
35. Bashaw J, Norris S, Weeks S, Trevino S, Adamovicz JJ, Welkos S. Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clin Vaccine Immunol 2007;14:605-16.
36. Cornelius CA, Quenee LE, Overheim KA, Koster F, Brasel L, Elli D, et al. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun 2008;76:5588-97.
37. Anderson DM, Ciletti NA, Lee-Lewis H, Elli D, Segal J, DeBord K, et al. Pneumonic plague pathogenesis and immunity in Brown Norway Rats. Am J Pathol 2009;174:910-21.
38. Jones SM, Day F, Stagg AJ, Williamson ED. Protection conferred by a fullyrecombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine 2001;19:358-66.
39. Powell BS, Andrews GP, Enama JT, Jendrek S, Ribot W, Bolt C, et al. Design and testing for a non-tagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Progr 2005;21:1490-510.
40. Williamson ED, Eley SM, Stagg AJ, Green M, Russell P, Titball RW. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 2001;19:566-71.
41. Williamson ED, Vesey PM, Gillhespy KJ, Eley SM, Green M, Titball RW. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol 1999;116:107-14.
42. Green M, Rogers D, Russell P, Stagg AJ, Bell DL, Eley SM, et al. The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol Med Microbiol 1999;23:107-13.
43. Hill J, Leary SEC, Griffin KF, Williamson ED, Titball RW. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunisation. Infect Immun 1997;65:4476-82.
44. Hill J, Copse C, Leary S, Stagg AJ, Williamson ED, Titball RW. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun 2003;71:2234-8.
45. Williamson ED, Sharpe GEJ, Eley SM, Vesey PM, Pepper T, Titball RW, et al. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine 1996;14:1613-9.
46. Eyles JE, Elvin SJ, Westwood A, LeButt CS, Alpar HO, Somavarapu S, et al. Immunisation against plague by transcutaneous and intradermal application of sub-unit antigens. Vaccine 2004;22:4365-73.
47. Elvin SJ, Williamson ED. The F1 and V subunit vaccine protects against plague in the absence of IL-4 driven immune responses. Microb Pathogen 2000;29:223-30.
48. Elvin SJ, Williamson ED. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague. Microb Pathogen 2004;37: 177-84.
49. Williamson ED, Stagg AJ, Eley SM, Taylor R, Green M, Jones SM, Titball RW. Kinetics of the immune response to the (F1 +V) vaccine in models of bubonic and pneumonic plague. Vaccine 2007;25:1142-8.
50. Huang J, D'Souza J, Alarcon JB, Mikszta JA, Ford BM, Ferriter MS, et al. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine. Clin Vaccine Immunol 2009;16: 719-25.
51. Elvin SJ, Williamson ED. Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine. Vaccine 2006;24: 4433-9.